Navigation Links
WaferGen Bio-systems Reports Completion of $15 Million Private Placement Transaction
Date:10/2/2013

FREMONT, Calif., Oct. 2, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today that it has completed a private placement to accredited investors of $15,037,500 of units consisting of shares of common stock, shares of Series 1 convertible preferred stock and warrants to purchase shares of common stock.

As previously announced, at the initial closing of the offering on August 27, 2013, the Company sold $13,668,500 of units for net proceeds of approximately $12,300,000.  At a subsequent closing on September 30, 2013, the Company sold an additional $1,369,000 of units for net proceeds of approximately $1,200,000.  In the private placement, the Company issued a total of 5,893,750 shares of common stock, 646 shares of Series 1 preferred stock (with a $0.001 per share liquidation preference and convertible into a total of 1,625,000 shares of Common Stock) and 3,759,379 five-year warrants with a $2.60 exercise price.  For additional details regarding the private placement, please see the current report on Form 8-K filed by the Company on August 28, 2013.

National Securities Corporation acted as sole placement agent in connection with the Offering and received compensation of approximately $1,300,000 cash and warrants to purchase 35.88 units at an initial exercise price of $50,000 per unit.

As previously reported, immediately prior to the initial closing of the private placement, the Company completed a restructuring transaction pursuant to which the Company exchanged shares of Series A-1 preferred stock with a liquidation preference of approximately $17.1 million, convertible notes with a principal amount of approximately $17.1 million and warrants exercisable for 565,180 shares of common stock for 2,987 shares of Series 1 preferred stock (with a $0.001 per share liquidation preference and convertible into a total of 7,513,372 shares of Common Stock), 1,067,317 shares of common sto
'/>"/>

SOURCE WaferGen Bio-systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. WaferGen Bio-systems Announces New Funding from Private Placement
2. WaferGen Launches SmartChip TE - A Novel Target Enrichment Solution for Next-Gen Sequencing (NGS) Aimed at Clinical Applications
3. WaferGen Bio-systems Launches MyDesign - Setting a New Standard in Flexibility with an Open Format High-Throughput qPCR Platform
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
6. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
7. Allied Healthcare Products Reports Loss On Sales Decline
8. TPI Reports Fiscal Year 2013 Financial Results
9. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
10. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
11. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... Test builds on company,s suite of tests to ... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... new diagnostic assay designed to help physicians better ... infections. The company will introduce the Pneumococcal ...
... of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI ... Given With Standard Platelet TherapyKENILWORTH, N.J., March 12 ... ) Phase II trial of SCH 530348, a novel ... The Lancet and demonstrated that the investigational ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:7/29/2014)... Regardless of the good things that happen in ... those with. Love is about understanding, commitment and sharing ... also about overcoming all the challenges that a relationship ... women need to know how to understand guys. ... please visit the official website at http://www.dailygossip.org/enchant-him-review-7111 . ...
(Date:7/29/2014)... Daily Gossip indicates in its Acne No More ... beautiful and clear skin in just 30 to 60 days. ... results even sooner than that. The new method was created ... step by step program, too. , Mike Walden claimed ... battled this condition for a decade and none of the ...
(Date:7/29/2014)... (HealthDay News) --,The time at which heart attack patients ... survival, new research suggests. Showing up at the ... is associated with a 13 percent higher risk for ... Every year, more than 250,000 people suffer a ... heart attack, which is caused by a complete blockage ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Chlorine helps keep pool ... likely to develop eye infections, doctors say. ... well as blurry vision, said Dr. Sampson Davis, an ... New Jersey. It,s important to understand why this ... away the outer film layer of the eye that ...
Breaking Medicine News(10 mins):Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Acne No More Review Reveals Most Effective Acne Cure Program 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2
... serious complications, researchers say , THURSDAY, Oct. 22 (HealthDay ... scans are better than standard X-rays at detecting the ... known as swine flu. , Researchers examined seven patients ... all of them. Three of the patients also received ...
... social interaction, researchers say , WEDNESDAY, Oct. 21 (HealthDay ... with autism has been identified by U.S. researchers, who ... diagnose and treat the disorder. , This genetic signature ... to the way that genes are switched on and ...
... to new treatments , WEDNESDAY, Oct. 21 (HealthDay News) ... that the gene behind Gaucher disease, a rare neurological ... those of us who work with rare disorders, it ... applicable to more common disorders," said Dr. Ellen Sidransky, ...
... women have tougher time shedding those excess pounds, study finds ... gain more than 15 pounds during pregnancy tend to retain ... finds. , Oregon researchers collected data on almost 1,700 obese ... gave birth between 2000 and 2005. , "We found that ...
... plans to rethink testing for breast, prostate tumors, contrary ... -- The American Cancer Society says it is not ... widely reported Wednesday. , "We are not redoing or ... going to restate our guidelines to emphasize the inadequacies ...
... Ohio It was once thought that the two communities ... cells and the normal cells that surround them existed ... cells encouraged cells within the tumor to become malignant, but ... new study led by Ohio State University cancer researchers published ...
Cached Medicine News:Health News:Less Sensitivity to Hormone May Play Role in Autism 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 3Health News:For Obese, Weight Gained in Pregnancy May Not Leave 2Health News:For Obese, Weight Gained in Pregnancy May Not Leave 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 2Health News:American Cancer Society Stands By Cancer Screening Guidelines 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 4Health News:Study shows how normal cells influence tumor growth 2
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... planned ECCE with peristaltic pump with ... suction, reflux possible with multi-function footswitch ... all critical functions. You can also ... actual vacuum level indicated by Bar ...
Medicine Products: